Paul Haberman is a distinguished Principal Engineer and mRNA Drug Substance Lead at Sanofi, where he plays a pivotal role in the Global Process Harmonization and Tech Transfer (GPH & TT) teams. With a robust academic foundation in Chemical Engineering and Engineering and Public Policy...
Paul Haberman is a distinguished Principal Engineer and mRNA Drug Substance Lead at Sanofi, where he plays a pivotal role in the Global Process Harmonization and Tech Transfer (GPH & TT) teams. With a robust academic foundation in Chemical Engineering and Engineering and Public Policy from Carnegie Mellon University, Paul has cultivated a unique blend of technical expertise and strategic insight, enabling him to navigate the complexities of the biotech landscape effectively.
Since transitioning to Sanofi following the acquisition of Translate Bio, Paul has emerged as a subject matter expert (SME) in mRNA Drug Substance development. His leadership in transferring mRNA and lipid nanoparticle (LNP) Good Manufacturing Practice (GMP) manufacturing processes to Sanofi's headquarters in MLE has been instrumental in scaling up production capabilities to meet the demands of Phase 3 clinical trials and eventual commercial production. His adeptness in process engineering and regulatory submissions has not only streamlined operations but also ensured compliance with stringent industry standards.
Paul's key projects reflect his commitment to innovation and excellence in biologics. His work in external manufacturing and process development has been critical in enhancing the efficiency and reliability of mRNA therapeutics. With a strong emphasis on statistics and biochemistry, he leverages data-driven approaches to optimize protein purification processes, thereby contributing to the advancement of cutting-edge therapies. As he continues to lead initiatives that harmonize global processes and facilitate technology transfer, Paul remains at the forefront of the rapidly evolving biotech sector, driving impactful solutions that enhance patient outcomes.
